A phase II clinical trial (NCT03353675) enrolled patients with advanced, untreated NSCLC with less than 50% PD-L1 expression after first-line chemotherapy; participants received the vector vaccine MVA-MUC1-IL2, also named as TG410, which includes a modified virus carrying the MUC1 protein and interleukin-2, alongside nivolumab, but the results have not been reported yet [45]. Here, IL2 is linked to non-small cell lung carcinoma.